Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
The efficacy and safety of the Cefaly (R) medical device for migraine treatment had already been reported early 2013 in the scientific journal "Neurology" (Official Journal of the American Academy of Neurology). Published data on a large number of individuals confirm the significant improvement for a majority of patients. Following 2 months of treatment, 54.4% of the patients described a very substantial improvement and decided to purchase the device. If we rule out those patients who didn't use the device or who only used it to a negligible degree, and take into account only regular users, the percentage of patients with a very significant improvement reaches 81%. Side effects are reported by only 4.3% of patients, all of which are minor and completely reversible. Therefore the effectiveness/safety ratio is excellent.
Current anti-migraine medications are only moderately effective and often not well tolerated. In addition, overuse of anti-migraine medications is an essential factor in the worsening of the disease and its development into chronic migraine. Cefaly (R) is therefore a means of choice to treat a majority of migraine patients.
Cefaly(R) is an innovative medical device protected by a number of patents. It is the first device to offer external cranial neurostimulation. Cranial neurostimulation is a technique that has been used for a number of years in neurology, but this has been carried out using implantable neurostimulators (similar to pacemakers). The technological advances made by Cefaly means that there is now a simple, lightweight, economical and comfortable device available that offers migraine patients a method of treatment that is neither drug-based nor invasive.
A self-adhesive electrode is placed on the forehead and the device is positioned on this electrode, worn like a pair of glasses. Highly precise impulses are transmitted through the electrode to the nerve endings of the upper branch of the trigeminal nerve.
The Cefaly(R) medical device is available on the European market and in Canada; FDA approval for USA is expected in the coming months.
Safety and patients’ satisfaction of transcutaneous Supraorbital NeuroStimulation (tSNS) with the Cefaly® device in headache treatment: a survey of 2,313 headache sufferers in the general population, Delphine Magis, Simona Sava, Tullia Sasso d’Elia, Roberta Baschi, Jean Schoenen, The Journal of Headache and Pain December 2013 - DOI 10.1186/1129-2377-14-95
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Headache / Migraine category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Technology, CEFALY. "Drug-free migraine treatment Cefaly®: Publication of a study conducted on 2,313 patients." Medical News Today. MediLexicon, Intl., 10 Jan. 2014. Web.
24 Apr. 2014. <http://www.medicalnewstoday.com/releases/271011>
Technology, C. (2014, January 10). "Drug-free migraine treatment Cefaly®: Publication of a study conducted on 2,313 patients." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/271011.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT is the registered trade mark of MediLexicon International Limited.